Hepatitis B virus mutants associated with 3TC and Famciclovir administration are replication defective

Hepatology

Volumn 27, Issue 2, 1998, Pages 628-633

  Melegari, Margherita ^a   Scaglioni, Pier Paolo ^a   Wands, Jack R ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAMCICLOVIR; LAMIVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; DNA SYNTHESIS; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENOME; VIRUS MUTANT; VIRUS REPLICATION;

2-AMINOPURINE; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BLOTTING, NORTHERN; CARCINOMA, HEPATOCELLULAR; CELL LINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; HYDROXYUREA; LAMIVUDINE; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEIC ACID SYNTHESIS INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0031938029     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510270243     Document Type: Article

References (14)

1. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119:312-323.
2. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and the related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499.
3. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
4. Lai CL, Ching CK, Tung AKM, Li E, Young J, Hill A, Wong BCY, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatits B surface antigen carriers: a placebo-controlled trial. HEPATOLOGY 1997;25:241-244.
5. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269: 696-699.
6. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989;12:3867-3874.
7. Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, van Kuilenburg ABP, van Gennip AH, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996;15:4040-4049.
8. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-415.
9. Ling RD, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplanted recipients with lamivudine. HEPATOLOGY 1996;24:711-713.
10. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in the HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996;24:714-717.
11. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
12. Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine) in vitro. Antimicrob Agents Chemother 1996;40:1957-1960.
13. Aye TT, Bartholomeusz AJ, Shaw T, Bowden DS, Breschkin AM, McMillan JS, Angus P, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997;26:1148-1153.
14. Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 1997;71:345-353.